GTC
CRVS icon

Ghost Tree Capital’s Corvus Pharmaceuticals CRVS Stock Holding History

Ghost Tree Capital’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$2.64M Buy
+500,000
New +$1.8M 0.8% 42

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ghost Tree Capital's CRVS Position: Q3 2024 in Review

Ghost Tree Capital opened a new position in Corvus Pharmaceuticals (CRVS) in Q3 2024: 500,000 shares worth $2.64M. The stake represents 0.8% of the portfolio and ranks #42 among its holdings.

62 funds tracked by Wall St. Rank hold CRVS as of Q3 2024.

  • Ghost Tree Capital held 500,000 shares of Corvus Pharmaceuticals worth $2.64M as of Q3 2024.
  • Corvus Pharmaceuticals was a new Ghost Tree Capital position in Q3 2024.
  • Corvus Pharmaceuticals made up 0.8% of Ghost Tree Capital's portfolio in Q3 2024, its #42 holding.
  • 62 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.